Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
企業コードPEN
会社名Penumbra Inc
上場日Sep 18, 2015
設立日2004
最高経営責任者「CEO」Mr. Adam Elsesser, J.D.
従業員数4500
証券種類Ordinary Share
決算期末Sep 18
本社所在地One Penumbra Place
都市ALAMEDA
証券取引所NYSE Consolidated
国United States of America
郵便番号94502
電話番号15109952486
ウェブサイトhttps://www.penumbrainc.com/
企業コードPEN
上場日Sep 18, 2015
設立日2004
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし